Email this article Superhigh doses of dexamethasone in the treatment of refractory forms of acute lymphoblast leukemia of adults
- Authors: Parovichnikova EN1, Savchenko VG1, Isaev VG1, Sokolov AN1, Moskov VI2, Klyasova GA1, Galtseva IV1, Ustinova EN1, Gribanova EO1, Lapin VA3, Zagoskina TP4
-
Affiliations:
- ГНЦ РАМН, Москва
- Краевая клиническая больница, Красноярск
- Городская клиническая больница № 8, Ярославль
- НИИ гематологии и переливания крови, Киров
- Issue: Vol 78, No 7 (2003)
- Pages: 21-24
- Section: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/33344
- ID: 33344
Cite item
Full Text
Abstract
vincristin, a-asparaginase) in patients with refractory acute lymphoblastic leukemia (ALE).
Material and methods. A pilot multicenter trial with participation of hematological departments of Hematological
Research Center (Moscow), municipal hospital N 1 (Krasnoyarsk), municipal hospital N\8
(Yaroslavl), Research Institute of Hematology and Blood Transfusion (Kirov) included 34 patients (jtQ
patients with late recurrences, 24 - with primary resistant forms, early and secondary recurrences)
Results. In patients with late ALL recurrences a complete remission (CR) was achieved in 70% cases,
the median being 10 months. In patients with primary resistant ALL, early and secondary recurrences
CR reached 37.5%, the median was 14 months.
Conclusion. The program HiDexa is highly effective : overall complete remission rate reached 47%,
median of complete remission duration was 10 months. Dexamethasone in high doses must be used only
intravenously.
About the authors
E N Parovichnikova
ГНЦ РАМН, МоскваГНЦ РАМН, Москва
V G Savchenko
ГНЦ РАМН, МоскваГНЦ РАМН, Москва
V G Isaev
ГНЦ РАМН, МоскваГНЦ РАМН, Москва
A N Sokolov
ГНЦ РАМН, МоскваГНЦ РАМН, Москва
V I Moskov
Краевая клиническая больница, КрасноярскКраевая клиническая больница, Красноярск
G A Klyasova
ГНЦ РАМН, МоскваГНЦ РАМН, Москва
I V Galtseva
ГНЦ РАМН, МоскваГНЦ РАМН, Москва
E N Ustinova
ГНЦ РАМН, МоскваГНЦ РАМН, Москва
E O Gribanova
ГНЦ РАМН, МоскваГНЦ РАМН, Москва
V A Lapin
Городская клиническая больница № 8, ЯрославльГородская клиническая больница № 8, Ярославль
T P Zagoskina
НИИ гематологии и переливания крови, КировНИИ гематологии и переливания крови, Киров
References
- Hoeltier D., Gokbugen N. New approaches to acute lymphoblastic leukemia in adults: where do we go? Semin. Oncol. 2000; 27: 540-549.
- Larson R., Stock W., Hoeltzer D., Kantarjian H. Acute lymphoblastic leukemia in adults. Washington: ASH Educational Book; 1998. 44-62.
- Савченко В. Г., Исаев В. Г., Кучер Р. А. Программа RACOP в терапии острого лимфобластного лейкоза взрослых. В кн.: Материалы III Всесоюзного съезда гематологов и трансфузиологов. Киров; 1991. 186.
- Соколов А. Н. Лечение рецидивов и резистентных форм острых лейкозов: Дис... канд. мед. наук. М.; 2000.
- Kaspers G. J., Veerman A. J., Popp-Snijders C. et al. Comparison of the antileukemia activity in vitro of dexamethasone and prednisone in childhood acute lymphoblastic leukemia. Med. Pediatr. Oncol. 1996; 27 (2): 114-121.
- Put С. Н. Childhood leukemias. N. Engl. J. Med. 1995; 332: 1618-1630.
- Koller С. A., Kantarjian H., O'Brien S. et al. Hyper-CVAD regimen improves outcome in relapsed acute lymphoblastic leukemia. Blood 1997; 90 (10, suppl. I): abstr. 1482.
